Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...
Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...
TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...
Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...
Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...
The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...
Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...